Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eylea
Pharma
Settlement allows Sandoz to launch Eylea biosimilar in late 2026
Regeneron and Sandoz have resolved patent litigation related to a biosimilar version of Eylea, allowing it to launch in the fourth quarter of 2026.
Kevin Dunleavy
Sep 9, 2025 10:30am
Novo plant acquired in Catalent deal lands in FDA's crosshairs
Aug 22, 2025 10:49am
Manufacturing issues cause FDA to delay decisions on Eylea HD
Aug 20, 2025 2:32pm
Issues at Novo Nordisk’s Indiana site trip up Regeneron again
Aug 1, 2025 11:51am
Regeneron's Eylea franchise stumbles on several fronts in Q1
Apr 29, 2025 2:50pm
Bayer wins appeal in case of ‘warming’ market for Eylea launch
Apr 29, 2025 9:00am
